Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed unresectable non-metastatic adenocarcinoma of the pancreas~* The American Joint Committee on Cancer (AJCC) stage I-III with unresectable or borderline unresectable disease as defined by NCCN guidelines~* Radiological resectability is defined by the following criteria on abdominal imaging:~  1. No evidence of tumor extension to the celiac axis, hepatic artery or superior mesenteric artery.~ 2. No evidence of tumor encasement or occlusion of the superior mesenteric vein (SMV) or the SMV/portal vein confluence~ 3. No evidence of visceral or peritoneal metastases~* Borderline and Unresectable cases would be defined as those that do not meet the criteria in section and also show no evidence of distant metastatic or intraperitoneal disease.~* Eastern Cooperative Oncology Group performance status of ≤ 2~* Age \> 18 years~* Adequate hematologic reserve, hepatic reserve and renal function~* White Blood Cell (WBC) \> 2,000 cells/mm3~* Absolute Neutrophil Count (ANC) \> 1,500 cells/mm3~* Platelets \> 100,000 cells/mm3~* Serum bilirubin ≤ 2.5 mg/dL~* Serum creatinine ≤ 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥ 30ml/min~* Alanine aminotransferase (ALT) \< 3 times ULN~* Aspartate transaminase (AST) \< 3 times ULN~* Albumin \> 3.2 g/dl~* Patient must sign study-specific informed consent~Exclusion Criteria:~* AJCC stage IV with metastatic disease~* Eastern Cooperative Oncology Group performance status of \> 2~* Age \< 18 years~* WBC \< 2,000 cells/mm3~* ANC \< 1,500 cells/mm3~* Platelets \> 100,000 cells/mm3~* Serum bilirubin \> 2.5 mg/dL~* Serum creatinine \> 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥ 30ml/min~* ALT \> 3 times ULN~* AST \> 3 times ULN~* Albumin \< 3.2 g/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proton Radiation (Type: EXPERIMENTAL): Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43~PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.~Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed~Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy